Vector Labs Ab03054-10.3 Anti-CD7 [TH69], Human IgG1, Fc Silent™, kappa (200 μg) Centrifuge Bundle Savings at Sycamore Life Sciences

Description

Product Class: Purified
Clone ID: TH69
Heavy Chain Modification: Fc Silent™
Synonyms: GP40; TP41; T-cell antigen CD7; T-cell leukemia antigen; T-cell surface antigen Leu-9; TH-69
Amount: 200 μg
Application Codes Clone: FC; block;
Shipping Temperature: Wet Ice
Buffer Composition: PBS with 0.02% Proclin 300.
Original Format: IgG1
Storage Temperature: Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement: This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG1 format for improved compatibility with existing reagents assays and techniques.
Specificity Statement: This antibody binds the extracellular domain of human CD7. CD7 is expressed on the majority of immature and mature T-lymphocytes, and T cell leukemia. It is also found on natural killer cells, a small subpopulation of normal B cells and on malignant B cells. CD7 is useful in the identification of precursor T cells as well as an important marker for the identification of leukemic T cells.
Application Notes: The therapeutic application of this antibody was explored to determine its potential use in the treatment of Human T-cell acute lymphocytic leukemia (ALL). When nude mice bearing approx. 2 g of tumor were treated with a single injection of CD7 antibody TH-69, 82.6% reached complete remission within 10 d whereas 13.0% showed partial remission. (PMID: 8904888). This antibody was also used in the development of a recombinant immunotoxin by linking the scFv version of this antibody to a truncated Pseudomonas exotoxin A fragment containing the catalytic domains II and III but lacking the receptor binding domain I. Approximately 20% of leukemic cells from a patient with CD7-positive acute T-cell leukemia kept in long-term primary culture for 30 cell generations were killed within 96 h after treatment with the toxin (PMID: 12019163). This antibody was also used in the generation of a fusion protein scFvCD7:sFasL, that is designed to have leukemia-restricted activity. wherein the scFv version of this antibody is genetically linked to soluble homotrimeric FasL. Treatment of T-cell acute lymphoblastic leukemia (T-ALL) cell lines and patient-derived T-ALL, peripheral T-cell lymphoma (PTCL), and CD7-positive acute myeloid leukemia (AML) cells with homotrimeric scFvCD7:sFasL revealed potent CD7-restricted induction of apoptosis that was augmented by conventional drugs, farnesyl transferase inhibitor L-744832, and the proteasome inhibitor bortezomib (PMID: 16332967).

Product Class:	Purified
Clone ID:	TH69
Heavy Chain Modification:	Fc Silent™
Synonyms:	GP40; TP41; T-cell antigen CD7; T-cell leukemia antigen; T-cell surface antigen Leu-9; TH-69
Amount:	200 μg
Application Codes Clone:	FC; block;
Shipping Temperature:	Wet Ice
Buffer Composition:	PBS with 0.02% Proclin 300.
Original Format:	IgG1
Storage Temperature:	Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement:	This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG1 format for improved compatibility with existing reagents assays and techniques.
Specificity Statement:	This antibody binds the extracellular domain of human CD7. CD7 is expressed on the majority of immature and mature T-lymphocytes, and T cell leukemia. It is also found on natural killer cells, a small subpopulation of normal B cells and on malignant B cells. CD7 is useful in the identification of precursor T cells as well as an important marker for the identification of leukemic T cells.
Application Notes:	The therapeutic application of this antibody was explored to determine its potential use in the treatment of Human T-cell acute lymphocytic leukemia (ALL). When nude mice bearing approx. 2 g of tumor were treated with a single injection of CD7 antibody TH-69, 82.6% reached complete remission within 10 d whereas 13.0% showed partial remission. (PMID: 8904888). This antibody was also used in the development of a recombinant immunotoxin by linking the scFv version of this antibody to a truncated Pseudomonas exotoxin A fragment containing the catalytic domains II and III but lacking the receptor binding domain I. Approximately 20% of leukemic cells from a patient with CD7-positive acute T-cell leukemia kept in long-term primary culture for 30 cell generations were killed within 96 h after treatment with the toxin (PMID: 12019163). This antibody was also used in the generation of a fusion protein scFvCD7:sFasL, that is designed to have leukemia-restricted activity. wherein the scFv version of this antibody is genetically linked to soluble homotrimeric FasL. Treatment of T-cell acute lymphoblastic leukemia (T-ALL) cell lines and patient-derived T-ALL, peripheral T-cell lymphoma (PTCL), and CD7-positive acute myeloid leukemia (AML) cells with homotrimeric scFvCD7:sFasL revealed potent CD7-restricted induction of apoptosis that was augmented by conventional drugs, farnesyl transferase inhibitor L-744832, and the proteasome inhibitor bortezomib (PMID: 16332967).

Specifications

More Information
Brand	Vector Labs
UNSPSC	12161500

Reviews